Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
Oragenics Announces Closing of Public Offering
Oragenics Announces Proposed Public Offering
Oragenics Announces Pricing of Public Offering
Oragenics, Inc. Announces Leadership Transition
Oragenics Announces Expiration of Its Investment Banking Engagement Agreement
Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion
Oragenics Announces Termination of At-The-Market Offering Program